ClinicalTrials.gg
Enrolling by invitationNCT07264296IRISSARUpdated Dec 4, 2025

Implant-Related Infections in Patients With Skeletal Sarcomas

An observational study in Implant Infection, Skeletal Sarcoma and Hip Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Vastra Gotaland Region · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Sex
All
01

Study summary

The aim of this observational study is to gain knowledge on the microbial and immunological factors behind implant-related infections in patients with skeletal sarcoma.

The main research question the project aims to answer is:

  • Are immunological factors more important than microbial factors in peri-prosthetic joint infections in orthopaedic oncology patients?

Patients with skeletal sarcoma planned for primary surgery (tumour resection and replacement with a megaprosthesis) will be sampled intraoperatively to obtain a cross-section bone tissue slice at the resection margin, three soft tissue biopsies and joint fluid (if possible). Patients who develop a peri-prosthetic joint infection after their primary surgery will be sampled in a similar manner during revision surgery.

An additional group of patients with periprosthetic joint infection of a hip or knee prosthesis due to osteoarthritis will be sampled during their revision surgery (bone biopsies, soft tissue biopsies and joint fluid, if possible).

Blood samples will be taken from all patients pre-operatively for extensive biochemical and cellular analyses.

Researchers will compare periprosthetic tissues before and after infection. Further, periprosthetic infected tissues in patients treated for skeletal sarcoma will be compared to periprosthetic infected tissues in patientens treated for osteoarthritis. This will be done to attempt to identify host and microbial mechanisms responsible for the increased infection rate in patients with a megaprosthesis due to skeletal sarcoma (infection incidence rate up to 30%) compared to patients with a hip or knee prosthesis due to osteoarthritis (infection incidence rate 1-2%).

Read the detailed description

In orthopaedic oncology, the risk and consequences of orthopaedic device related infections (ODRIs) are heightened as the patients often have compromised immune responses due to underlying disease, chemotherapy or radiation. The implants used may be weight-bearing to the extent that they are impossible to remove or exchange in case of infection, and thereby, in worst case, resulting in amputation or death. Compared to the 1-2% incidence of PJI in a non-oncological population with a total hip- or knee prosthesis, patients with a megaprosthesis due to skeletal sarcoma have an infection incidence of 3-25%. Patient-related factors, extensive and repeated surgery and large reconstructive implants likely account for the increased incidence.

To our knowledge no study has evaluated the role of microbiological factors such as the biofilm production and susceptibility in this population. Further, deficient immunological factors in these patients, such as defect neutrophil migration, cytokine expression and phagocyte respiratory burst, involved in the killing of microbes, may provide an environment favouring more virulent phenotypes. Fundamental knowledge on the role of biofilm in this population could add to the improvement in treatment planning and outcome.

Distinguishing causative pathogens from contaminants may be challenging, especially in polymicrobial infections. The addition of metagenomic diagnostics, still sparsely used in clinical practice, may improve sensitivities, but predictive accuracy is still an issue. Comparing the results of conventional microbiological culturing with metagenomic sequencing would be of interest to determine the accuracy of current diagnostic methods.

The present study is an exploratory project addressing the multifactorial nature of PJI focusing on microbial phenotype in patients with skeletal sarcoma. The role of host, microbe and implant factors will be investigated using a set of different methods and compared to cases och PJI in patients will a conventional hip- or knee prosthesis.

Pre-operative blood samples will be taken and samples of peri-prosthetic soft tissue, bone and joint fluid will be collected intra-operatively. Patients will be sampled during their primary operation with a megaprosthesis due to skeletal sarcoma and in case of postoperative PJI, they will be sampled in the same manner during their revision surgery. Patients undergoing a reoperation due to PJI in a conventional total hip- or knee prosthesis will also be sampled with blood, bone, soft tissue and joint fluid intraoperatively.

Descriptive comparisons between (i) periprosthetic tissues and PJI tissues before and after infection in orthopaedic oncology patients, and (ii) PJI tissues in orthopaedic oncology and conventional PJI patients, will be made in regard to the following parameters:

Role of the host:

  • Clinical parameters: ASA-score, diabetes, BMI, age, sex, antibiotic use 2 weeks prior to surgery, duration of chemotherapy, type of chemotherapy, chemotherapy cessation, symptom onset in case of infection, implant type, surgery duration, osteosarcoma type, grade and stage, location of surgery, length of resection.
  • Biochemistry in blood (complete white blood cell count with differential, density of neutrophils, CRP, procalcitonin, IL-6).
  • Histology and immunohistochemistry (FISH for identification of bacteria, inflammatory infiltrates (presence of foreign body giant cells), angiogenesis, tissue necrosis)
  • Gene expression (markers related to angiogenesis, inflammation, microbial recognition and tissue necrosis). In selected paraffin-embedded samples, analysis with spatial transcriptomics will be explored.

Role of the pathogen:

  • Five tissue cultures for routine culturing (to determine the causative agent) and one additional for bacterial DNA extraction and 16S rRNA gene sequencing.
  • Clinical staphylococcal strains isolated from PJI and tumour endoprosthesis at time of infection will be characterised and compared with respect to their phenotypic biofilm production, antimicrobial susceptibility and presence of virulence genes using CV, MBEC and NGS.
  • Difference in gene expression of biofilm-related genes between staphylococcal PJI strains (conventional \& orthopaedic oncology) when grown on titanium with serum pre-conditioning in vitro.
02

Conditions studied

  • Implant Infection
  • Skeletal Sarcoma
  • Hip Arthritis
  • Prosthesis-Related Infections
  • Knee Arthritis

Keywords

  • Biofilm
  • Periprosthetic joint infection
  • Skeletal sarcoma
03

In context

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 99 observational studies indexed under Osteosarcoma.

Browse Osteosarcoma studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Three groups of patients will be studied:

  • Patients who undergo surgery with a megaprosthesis due to skeletal sarcoma
  • Patients who have a PJI of a megaprosthesis
  • Patients who have a PJI after total hip or knee replacement due to osteoarthritis

All patients will be recruited consecutively at the Sahlgrenska University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with skeletal sarcoma planned for primary surgery with resection of tumour and replacement with a megaprosthesis.
  • Patients operated with a megaprosthesis due to skeletal sarcoma who develop a peri-prosthetic joint infection (PJI).
  • Patients diagnosed with PJI after total hip or knee replacement due to osteoarthritis.

Exclusion criteria

Exclusion Criteria:

  • None in the group of patients with skeletal sarcoma.
  • Patients in the PJI group who have a total hip or knee replacement are excluded if they use immunomodulary medication or have a immunodeficiency.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Skeletal sarcoma group

    Patients who receive a megaprosthesis as a primary procedure for skeletal sarcoma.

  • Periprosthetic joint infection after skeletal sarcoma

    Patients with a periprosthetic joint infection after surgery with a megaprosthesis due to skeletal sarcoma.

  • Periprosthetic joint infection after hip/knee replacement due to osteoarthritis

    Non-immuncompromised patients with periprosthetic joint infection following a primary total hip or knee replacement.

06

What researchers measure

Primary outcomes

  1. Difference in virulence properties in causative microbes in the two groups of PJI

    A descriptive analysis of genotype will be conducted

    Time frame: Sampling will occur intraoperatively, bacteria will be frozen, no time frame neccessary

Secondary outcomes

  1. Differences in periprosthetic tissues in the two PJI groups

    Descriptive analysis of periprosthetic tissue using histological methods

    Time frame: Sampling will occur intraoperatively, tissues will be preserved, no time frame neccessary

Other outcomes

  1. Differences in biofilm production ability between causative microbes in the two PJI groups

    Biofilm production will be assesed and categorised into none/weak and moderate/strong

    Time frame: Sampling will occur intraoperatively, bacteria will be frozen, no time frame neccessary

07

Study locations

1 site
  • Ortopedi, Sahlgrenska University Hospital
    Gothenburg, Sweden
08

References and documents

Individual participant data

Plan to share: No — The main results will be presented at an aggregated level. In some cases, individual data may be presented (e.g. characteristics of a bacterial strain in relation to clinical outcome), but this information will be unidentified so that it cannot be deduced to the individual. All compiled personal data will be stored on a password-protected hospital server that only the research group has access to. No personal data will be reported in publications. The results of the study will be documented according to the study protocol and placed in a journal. Participants will be coded in a document together with the social security numbers. Information about the participants, their health and the code key will be collected at the Orthopaedic Clinic where it will be treated confidentially and securely for 10 years. The handling of the participants' information is regulated by the Personal Data Act (SFS 1998: 204).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

Of 41 observational studies under Osteosarcoma, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 228. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
Dec 4, 2025
StartActual
Feb 5, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jan 31, 2028
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264296
Collaborators
Göteborg University, The Swedish Society of Medicine, Sahlgrenska University Hospital
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Feb 5, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Dec 4, 2025

Study contacts

Karin Svensson Malchau, PhD
principal investigator · Vastra Gotaland Region
Margarita Trobos, Assoc Prof
principal investigator · Göteborg University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion